A Randomized Phase II Study Comparing Single-Agent Olaparib, Single-Agent Cediranib, and the Combinations of Cediranib/olaparib, Olaparib/durvalumab (MEDI4736), Cediranib/durvalumab (MEDI4736), and Olaparib/azd5363 (capivasertib) in Women with Recurrent, Persistent, or Metastatic Endometrial Cancer.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
Olaparib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要